Airway Therapeutics has completed the dose escalation part of its Phase Ib trial of zelpultide alfa (AT-100) for preventive use in very preterm infants at bronchopulmonary dysplasia (BPD) risk.

Designed to establish the safety and tolerability of zelpultide alfa, the randomised, blinded, air-sham controlled trial is being conducted in the US and Spain.

The company started enrolling patients from the previous month for daily treatment up to seven days using the highest dose of zelpultide alfa (rhSP-D).

This dose was administered to the patients, after a Data Safety Monitoring Committee (DSMC) reported no safety concerns.

Airway’s subsidiary Airway Spain will lead the Phase Ib trial and subsequent clinical trials across the EU.

Airway CEO and chief medical officer Marc Salzberg said: “This is a significant milestone in our efforts to protect these infants from suffering severe BPD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The very favourable safety profile is particularly important in these extremely vulnerable preterm neonates. The DSMC confirmed the excellent safety profile of zelpultide alfa following completion of the third cohort of infants who received the highest dose.

“This dose is being used in a fourth and final cohort which now also includes infants born at 23 – 24 weeks, the earliest gestational age in our study.”

The company plans to announce interim analysis data in the second quarter of this year.

Apart from treating BPD, Zelpultide alfa is used for treating Covid/CAP in seriously ill mechanically ventilated patients.